Abstract
alterations in NFE2L2 and KEAP1 confer poorer overall survival (P Z 0.02). Conclusions: The integrative, high-throughput methods shown here for large-scale profiling of radiation survival and genomic features of solidtumor derived cell lines should facilitate tumor radiogenomics and the discovery of radiation sensitizers and protective agents. The potential clinical translation of these findings includes the development of NFE2L2 molecular diagnostics and the prospective validation of the first radiotherapeutic resistance biomarker in lung NSCLC. Author Disclosure:M. Abazeed: None. C. Xu: None. D. Adams: None. P. Tamayo: None. J. Loeffler: None. J. Suh: None. M. Meyerson: G. Consultant; MM is a consultant to Foundation Medicine. R. Ownership Other; MM is an equity holder in Foundation Medicine. K. Wong: None. P. Hammerman: G. Consultant; P.S.H. reports consulting fees from ARIAD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
